{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:56:57Z","timestamp":1794315417386,"version":"4.9.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Intestinal Beh\u00e7et\u2019s disease (BD) is characterized by typical gastrointestinal ulcers in patients with BD followed by complications such as bleeding, perforation and fistula. Biologic agents are currently under active investigation to delay the disease course. Various data regarding infliximab are available, but there is relatively lack of data regarding adalimumab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a multicenter, real-world prospective observational study to evaluate the effectiveness and safety of adalimumab in intestinal BD. The primary endpoint was disease activity at each follow up, including disease activity index for intestinal Beh\u00e7et\u2019s disease (DAIBD), serum C-reactive protein (CRP) level, and endoscopic findings. The secondary endpoint was the incidence of adverse drug reactions (ADRs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 58 patients were enrolled and 8 of them were excluded. Adverse events were reported in 72.0% of patients with 122 events. ADRs were reported in 24.0% with 28 events. For adverse events, arthralgia was most commonly reported (13.1%: 16\/122) and only one experienced critical adverse event (0.82%, 1\/122: death due to stroke). On multivariable regression analysis, a longer disease duration was significantly associated with decreased ADRs [Odds ratio 0.976 (0.953\u20130.999, 95% CI); <jats:italic>p\u2009=<\/jats:italic>\u20090.042]. Clinical response rates as assessed by DAIBD were 90.9% at Week 12 and 89.7% at Week 56, respectively. The mean serum CRP level at baseline was significantly decreased after 12 weeks (3.91\u2009\u00b1\u20094.93 to 1.26\u2009\u00b1\u20092.03\u00a0mg\/dL; <jats:italic>p<\/jats:italic>\u2009=\u20090.0002).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Adalimumab was found to be safe and effective in Korean patients with intestinal BD. A longer disease duration was significantly associated with decreased ADRs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-023-03090-x","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T10:02:29Z","timestamp":1702980149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness and safety of adalimumab in patients with intestinal Beh\u00e7et\u2019s disease: a real-world prospective observational study in South Korea"],"prefix":"10.1186","volume":"23","author":[{"given":"Jongwook","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Jae","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yune-Jung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-In","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byong Duk","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geun-Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Kook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonjeong","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hee","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"issue":"1","key":"3090_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-021-00301-1","volume":"7","author":"Y Yazici","year":"2021","unstructured":"Yazici Y, Hatemi G, Bodaghi B, Cheon JH, Suzuki N, Ambrose N, Yazici H. Behcet syndrome. Nat Rev Dis Primers. 2021;7(1):67.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"3090_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3904\/kjim.2017.377","volume":"33","author":"YE Park","year":"2018","unstructured":"Park YE, Cheon JH. Updated treatment strategies for intestinal Behcet\u2019s Disease. Korean J Intern Med. 2018;33(1):1\u201319.","journal-title":"Korean J Intern Med"},{"issue":"3","key":"3090_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12328-014-0488-0","volume":"7","author":"T Hisamatsu","year":"2014","unstructured":"Hisamatsu T, Naganuma M, Matsuoka K, Kanai T. Diagnosis and management of intestinal Behcet\u2019s Disease. Clin J Gastroenterol. 2014;7(3):205\u201312.","journal-title":"Clin J Gastroenterol"},{"issue":"6","key":"3090_CR4","doi-asserted-by":"publisher","first-page":"623","DOI":"10.5009\/gnl17462","volume":"12","author":"J Park","year":"2018","unstructured":"Park J, Cheon JH. Anti-tumor Necrosis factor therapy in intestinal Behcet\u2019s Disease. Gut Liver. 2018;12(6):623\u201332.","journal-title":"Gut Liver"},{"issue":"5","key":"3090_CR5","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1097\/MCG.0b013e3182431d56","volume":"46","author":"YS Jung","year":"2012","unstructured":"Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet Disease. J Clin Gastroenterol. 2012;46(5):e38\u201345.","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"3090_CR6","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1097\/MCG.0b013e3181c8a50f","volume":"44","author":"MJ Chung","year":"2010","unstructured":"Chung MJ, Cheon JH, Kim SU, Park JJ, Kim TI, Kim NK, Kim WH. Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behcet Disease. J Clin Gastroenterol. 2010;44(6):e116\u2013122.","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"3090_CR7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.5009\/gnl210062","volume":"16","author":"J Yu","year":"2022","unstructured":"Yu J, Hyun HK, Park J, Kang EA, Park SJ, Park JJ, Kim TI, Kim WH, Cheon JH. Continued postoperative use of Tumor Necrosis factor-alpha inhibitors for the Prevention of Crohn\u2019s Disease recurrence. Gut Liver. 2022;16(3):414\u201322.","journal-title":"Gut Liver"},{"issue":"7","key":"3090_CR8","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1002\/ibd.21517","volume":"17","author":"YS Jung","year":"2011","unstructured":"Jung YS, Yoon JY, Lee JH, Jeon SM, Hong SP, Kim TI, Kim WH, Cheon JH. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet\u2019s Disease. Inflamm Bowel Dis. 2011;17(7):1594\u2013602.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"3090_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12876-021-01922-2","volume":"21","author":"EA Kang","year":"2021","unstructured":"Kang EA, Park JW, Park Y, Park SJ, Kim TI, Kim WH, Cho MS, Cheon JH. C-reactive protein is associated with postoperative outcomes in patients with intestinal Behcet\u2019s Disease. BMC Gastroenterol. 2021;21(1):362.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"3090_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.5217\/ir.2019.09141","volume":"18","author":"Y Mori","year":"2020","unstructured":"Mori Y, Iwamoto F, Ishida Y, Kuno T, Kobayashi S, Yoshida T, Yamaguchi T, Sato T, Sudo M, Ichikawa D, et al. Long-term outcome after Surgery in a patient with intestinal Behcet\u2019s Disease complicated by Myelodysplastic Syndrome and trisomy 8. Intest Res. 2020;18(4):469\u201375.","journal-title":"Intest Res"},{"issue":"6","key":"3090_CR11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/MPG.0b013e318223652f","volume":"53","author":"I Iwama","year":"2011","unstructured":"Iwama I, Kagimoto S. Anti-tumor necrosis factor monoclonal antibody therapy for intestinal Behcet Disease in an adolescent. J Pediatr Gastroenterol Nutr. 2011;53(6):686\u20138.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"7","key":"3090_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.dld.2018.10.024","volume":"51","author":"N Sugimura","year":"2019","unstructured":"Sugimura N, Mizoshita T, Sugiyama T, Togawa S, Miyaki T, Suzuki T, Tanida S, Kataoka H, Sasaki M. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behcet\u2019s Disease. Dig Liver Dis. 2019;51(7):967\u201371.","journal-title":"Dig Liver Dis"},{"issue":"5","key":"3090_CR13","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1097\/MEG.0000000000002087","volume":"33","author":"A Tursi","year":"2021","unstructured":"Tursi A, Mocci G, Lorenzetti R, Allegretta L, Brandimarte G, Cassieri C, Colucci R, De Medici A, Faggiani R, Ferronato A, et al. Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel Diseases outpatients. Eur J Gastroenterol Hepatol. 2021;33(5):670\u20139.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9","key":"3090_CR14","first-page":"1833","volume":"19","author":"JH Lee","year":"2013","unstructured":"Lee JH, Cheon JH, Jeon SW, Ye BD, Yang SK, Kim YH, Lee KM, Im JP, Kim JS, Lee CK, et al. Efficacy of infliximab in intestinal Behcet\u2019s Disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19(9):1833\u20138.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"3090_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11894-020-00759-1","volume":"22","author":"Y Park","year":"2020","unstructured":"Park Y, Cheon JH. Update on the Treatment of Behcet\u2019s Disease of the small bowel with Biologic agents. Curr Gastroenterol Rep. 2020;22(5):24.","journal-title":"Curr Gastroenterol Rep"},{"issue":"4","key":"3090_CR16","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/jgh.15754","volume":"37","author":"M Zhang","year":"2022","unstructured":"Zhang M, Liu J, Liu T, Han W, Bai X, Ruan G, Lv H, Shu H, Li Y, Li J, et al. The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal Behcet\u2019s Disease, a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37(4):608\u201319.","journal-title":"J Gastroenterol Hepatol"},{"key":"3090_CR17","doi-asserted-by":"publisher","first-page":"109242","DOI":"10.1016\/j.clim.2023.109242","volume":"247","author":"TB van der Houwen","year":"2023","unstructured":"van der Houwen TB, Humer B, Missotten TO, Thiadens A, van Hagen PM, van Laar JAM. Long-term data on efficacy and safety of adalimumab in Behcet\u2019s Disease. Clin Immunol. 2023;247:109242.","journal-title":"Clin Immunol"},{"issue":"2","key":"3090_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11894-020-0745-y","volume":"22","author":"S Chang","year":"2020","unstructured":"Chang S, Hudesman D. First-line biologics or small molecules in inflammatory bowel Disease: a practical guide for the Clinician. Curr Gastroenterol Rep. 2020;22(2):7.","journal-title":"Curr Gastroenterol Rep"},{"issue":"2","key":"3090_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/00063030-200418020-00005","volume":"18","author":"LM Bang","year":"2004","unstructured":"Bang LM, Keating GM. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs. 2004;18(2):121\u201339.","journal-title":"BioDrugs"},{"issue":"5","key":"3090_CR20","doi-asserted-by":"publisher","first-page":"764","DOI":"10.5009\/gnl210335","volume":"16","author":"J Yu","year":"2022","unstructured":"Yu J, Park SJ, Kim HW, Lim YJ, Park J, Cha JM, Ye BD, Kim TO, Kim HS, Lee HS, et al. Effectiveness and safety of Golimumab in patients with Ulcerative Colitis: a Multicenter, prospective, Postmarketing Surveillance Study. Gut Liver. 2022;16(5):764\u201374.","journal-title":"Gut Liver"},{"issue":"3","key":"3090_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5217\/ir.2020.00013","volume":"19","author":"Y Suzuki","year":"2021","unstructured":"Suzuki Y, Hagiwara T, Kobayashi M, Morita K, Shimamoto T, Hibi T. Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behcet\u2019s Disease: results from a large real-world observational study. Intest Res. 2021;19(3):301\u201312.","journal-title":"Intest Res"},{"issue":"5","key":"3090_CR22","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.cgh.2014.08.042","volume":"13","author":"S Tanida","year":"2015","unstructured":"Tanida S, Inoue N, Kobayashi K, Naganuma M, Hirai F, Iizuka B, Watanabe K, Mitsuyama K, Inoue T, Ishigatsubo Y, et al. Adalimumab for the treatment of Japanese patients with intestinal Behcet\u2019s Disease. Clin Gastroenterol Hepatol. 2015;13(5):940\u2013948e943.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"3090_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10067-016-3417-4","volume":"36","author":"A Vitale","year":"2017","unstructured":"Vitale A, Emmi G, Lopalco G, Gentileschi S, Silvestri E, Fabiani C, Urban ML, Frediani B, Galeazzi M, Iannone F, et al. Adalimumab effectiveness in Behcet\u2019s Disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol. 2017;36(2):451\u20135.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"3090_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5217\/ir.2017.15.3.395","volume":"15","author":"N Inoue","year":"2017","unstructured":"Inoue N, Kobayashi K, Naganuma M, Hirai F, Ozawa M, Arikan D, Huang B, Robinson AM, Thakkar RB, Hibi T. Long-term safety and efficacy of adalimumab for intestinal Behcet\u2019s Disease in the open label study following a phase 3 clinical trial. Intest Res. 2017;15(3):395\u2013401.","journal-title":"Intest Res"},{"issue":"4","key":"3090_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.14740\/jocmr2477w","volume":"8","author":"S Tanida","year":"2016","unstructured":"Tanida S, Mizoshita T, Nishie H, Ozeki K, Katano T, Shimura T, Kubota E, Kataoka H, Kamiya T, Joh T. Long-term efficacy of Adalimumab in patients with intestinal Behcet\u2019s Disease: eight consecutive cases. J Clin Med Res. 2016;8(4):334\u20137.","journal-title":"J Clin Med Res"},{"key":"3090_CR26","unstructured":"Guideline IHT. Clinical safety data management: definitions and standards for expedited reporting E2A. In: International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use: 1994; 1994."},{"issue":"2","key":"3090_CR27","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/ibd.21313","volume":"17","author":"JH Cheon","year":"2011","unstructured":"Cheon JH, Han DS, Park JY, Ye BD, Jung SA, Park YS, Kim YS, Kim JS, Nam CM, Kim YN, et al. Development, validation, and responsiveness of a novel Disease activity index for intestinal Behcet\u2019s Disease. Inflamm Bowel Dis. 2011;17(2):605\u201313.","journal-title":"Inflamm Bowel Dis"},{"issue":"40","key":"3090_CR28","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.3748\/wjg.v18.i40.5771","volume":"18","author":"HJ Lee","year":"2012","unstructured":"Lee HJ, Kim YN, Jang HW, Jeon HH, Jung ES, Park SJ, Hong SP, Kim TI, Kim WH, Nam CM, et al. Correlations between endoscopic and clinical Disease activity indices in intestinal Behcet\u2019s Disease. World J Gastroenterol. 2012;18(40):5771\u20138.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"3090_CR29","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1002\/ibd.20869","volume":"15","author":"A Ariyachaipanich","year":"2009","unstructured":"Ariyachaipanich A, Berkelhammer C, Nicola H. Intestinal Behcet\u2019s Disease: maintenance of remission with adalimumab monotherapy. Inflamm Bowel Dis. 2009;15(12):1769\u201371.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"3090_CR30","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/ibd.20457","volume":"14","author":"M Naganuma","year":"2008","unstructured":"Naganuma M, Sakuraba A, Hisamatsu T, Ochiai H, Hasegawa H, Ogata H, Iwao Y, Hibi T. Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet\u2019s Disease. Inflamm Bowel Dis. 2008;14(9):1259\u201364.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"3090_CR31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s00535-013-0872-4","volume":"49","author":"T Hisamatsu","year":"2014","unstructured":"Hisamatsu T, Ueno F, Matsumoto T, Kobayashi K, Koganei K, Kunisaki R, Hirai F, Nagahori M, Matsushita M, Kobayashi K, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet\u2019s Disease: indication of anti-TNFalpha monoclonal antibodies. J Gastroenterol. 2014;49(1):156\u201362.","journal-title":"J Gastroenterol"},{"issue":"24","key":"3090_CR32","doi-asserted-by":"publisher","first-page":"e3863","DOI":"10.1097\/MD.0000000000003863","volume":"95","author":"T Hibi","year":"2016","unstructured":"Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, Kondo K, Ishigatsubo Y. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet Disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Med (Baltim). 2016;95(24):e3863.","journal-title":"Med (Baltim)"},{"key":"3090_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, Salvarani C, Lambert M, Bielefeld P, Seve P, et al. Efficacy of anti-TNF alpha in severe and\/or refractory Behcet\u2019s Disease: Multicenter study of 124 patients. J Autoimmun. 2015;62:67\u201374.","journal-title":"J Autoimmun"},{"issue":"3","key":"3090_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.5217\/ir.2019.00128","volume":"18","author":"JM Kim","year":"2020","unstructured":"Kim JM, Cheon JH. Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel Diseases. Intest Res. 2020;18(3):249\u201364.","journal-title":"Intest Res"},{"issue":"1","key":"3090_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.autrev.2013.06.005","volume":"13","author":"G Fiorino","year":"2014","unstructured":"Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel Disease patients receiving anti-TNF-alpha agents. Autoimmun Rev. 2014;13(1):15\u20139.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"3090_CR36","doi-asserted-by":"publisher","first-page":"e000667","DOI":"10.1136\/rmdopen-2018-000667","volume":"4","author":"S Alivernini","year":"2018","unstructured":"Alivernini S, Pugliese D, Tolusso B, Bui L, Petricca L, Guidi L, Mirone L, Rapaccini GL, Federico F, Ferraccioli G, et al. Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel Disease: histological and immunological features of a complex synovitis. RMD Open. 2018;4(1):e000667.","journal-title":"RMD Open"},{"issue":"1","key":"3090_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jbspin.2017.01.001","volume":"85","author":"M Sondag","year":"2018","unstructured":"Sondag M, Verhoeven F, Guillot X, Prati C, Briot C, Vuitton L, Koch S, Wendling D. Paradoxical arthralgia occurring under anti-TNFalpha treatment for inflammatory bowel Disease. Joint Bone Spine. 2018;85(1):133\u20134.","journal-title":"Joint Bone Spine"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-03090-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-03090-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-03090-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T10:03:32Z","timestamp":1702980212000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-03090-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3090"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-03090-x","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"3 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Byong Duk Ye has received consulting fees from AbbVie Korea, BMS Pharmaceutical Korea Ltd., Celltrion, Chong Kun Dang Pharm, CJ Red BIO, Curacle, Daewoong Pharma., Ferring Korea, IQVIA, Janssen Korea, Kangstem Biotech, Korea Otsuka Pharm., Korea United Pharm. Inc., Medtronic Korea, NanoEntek, ORGANOIDSCIENCES LTD., Pfizer Korea, Takeda, Takeda Korea; speaker fees from AbbVie Korea, Celltrion, Cornerstones Health, Curacle, Ferring Korea, Janssen Korea, Pfizer Korea, Takeda Korea, IQVIA; and research support from Celltrion and Pfizer Korea. Seonjeong Jeong is a former AbbVie employee. AbbVie sponsored the study; contributed to the design; participated in the collection, analysis, and interpretation of data; in writing, reviewing, and approval of the final version. No honoraria or payments were made for authorship. Otherwise, there are no authors and companies with conflict of interest in relation to the contents of the presentation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki, and was approved by the Institutional Review Board of each participating hospital [Yonsei University Health System Institutional Review Board (4-2015-1112); Ajou University Hospital Institutional Review Board (AJIRB-MED-OBS-15-458); The Catholic University of Korea St. Vincent\u2019s Hospital Institutional Review Board (VC17OODE0085); Pusan National University Yangsan Hospital Institutional Review Board (02-2017-009); Seoul St. Mary\u2019s Hospital, The Catholic University of Korea Institutional Review Board (KC15OSME0868); Asan Medical center Institutional review board (2016\u2009\u2212\u20090139); Kosin University Gospel Hospital Institutional Review Board (KUGH 2017-03-013); KyungPook National University Hospital Institutional Review Board (2015-12-010-001); Institutional review board, Clinical Research Institute, Seoul National University Hospital (H-1512-034-726); Samsung Medical Center Institutional Review Board (2015-11-133)]. All patients agreed to the conditions of the study and signed their informed consents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"449"}}